These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37043382)

  • 1. Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome.
    Moroni F; Ayers MP; Dixon DL; Abbate A
    J Cardiovasc Pharmacol; 2023 May; 81(5):336-338. PubMed ID: 37043382
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.
    Kim OM; Givens TK; Tang EG; Schimmer JJ; Ramsey T; Boyd K; Delate T
    J Cardiovasc Pharmacol; 2023 May; 81(5):339-347. PubMed ID: 36795508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
    Leong D; Wu PE
    CMAJ; 2019 Aug; 191(32):E894. PubMed ID: 31405836
    [No Abstract]   [Full Text] [Related]  

  • 4. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
    Canonico ME; Hess CN; Cannon CP
    Curr Atheroscler Rep; 2023 Jul; 25(7):381-389. PubMed ID: 37223853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk.
    White HD
    Heart; 2022 Jul; 108(16):1250-1252. PubMed ID: 35508402
    [No Abstract]   [Full Text] [Related]  

  • 6. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center.
    Tsai CL; Chang YH; Su CH; Wu YJ; Yeh HI; Lin CF
    J Formos Med Assoc; 2022 Sep; 121(9):1877-1880. PubMed ID: 34852937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance.
    Jia X; Al Rifai M; Saeed A; Ballantyne CM; Virani SS
    Vasc Health Risk Manag; 2022; 18():555-566. PubMed ID: 35898405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction.
    McKinley EC; Bittner VA; Brown TM; Chen L; Colantonio LD; Exter J; Orroth KK; Reading SR; Rosenson RS; Muntner P
    J Clin Lipidol; 2022; 16(1):75-82. PubMed ID: 34848176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings.
    Wang D; Zhang D
    Cardiol Rev; 2023 May-Jun 01; 31(3):155-161. PubMed ID: 35175957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 12. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
    Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
    Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
    Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
    Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
    Davis LE; Pogge EK
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein Convertase Subtilism/Kexin 9 (PCSK9) Inhibitors: Adding to the Armamentarium of the Primary Care Physician.
    Coy K; Stys A; Stys T; DeVries J
    S D Med; 2021 Oct; 74(10):454-456. PubMed ID: 34995425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
    Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
    Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
    Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.